Nurami Medical ⚠ Under review

About

Funding history · 12 rounds · $58.2M total

Offices

Q&A

What is Nurami Medical's primary focus?

Nurami Medical is a biotechnology company focused on advancing innovation in soft-tissue repair using nanofibers and engineered biomaterials to improve patient recovery.

When was Nurami Medical founded?

Nurami Medical was founded in 2014.

How many employees does Nurami Medical currently have?

Nurami Medical has 11-50 employees.

What was Nurami Medical's most recent funding round?

In March 2025, Nurami Medical secured a C Round of $30,000,000. The round included investors such as Israel Innovation Authority.

Has Nurami Medical received any grants recently?

Yes, in July 2024, Nurami Medical received a grant of $2,695,274 from the Israel Innovation Authority (IIA) and the European Innovation Council (EIC) Accelerator program.

Which product of Nurami Medical received FDA clearance?

Nurami Medical's ArtiFascia® Dura Substitute received FDA clearance in August 2023.

What was the amount and lead investors of Nurami Medical's B Round?

In November 2020, Nurami Medical raised $6,000,000 in a B Round led by.

What is ArtiFascia?

ArtiFascia is Nurami Medical's first soft-tissue repair product, a multilayer, Dural repair graft made of biocompatible and bioabsorbable polymers with an integrated barrier layer and a biomimetic structure of electrospun fibers designed to promote neodura regeneration. It is available for commercial use in the USA and has FDA 510(k) clearance.

Team · 5

Nora Nseir Manassa

Founder · Founder and Co-CEO, CTO

Amir Bahar

Founder · Founder, COO, Clinical Director

Hannoch Marksheid

Co-CEO, BD Manager

Nizar Mishael

CFO

Koby Gvili

General Manager Nurami Inc.

Sectors & technology

Highlights

Tags